

MAINTENANCE OF ENDOSCOPIC AND HISTOLOGIC EFFICACY WITH GUSELKUMAB FOR ULCERATIVE COLITIS AT WEEK 92 OF THE QUASAR LONG-TERM EXTENSION STUDY

Bruce E. Sands

UEG Week Berlin 2025

Presentation

IBD

Mechanisms & Personalised Medicine

October 7, 2025

In the QUASAR long-term extension, guselkumab subcutaneous maintenance therapy sustained endoscopic and histologic improvements in ulcerative colitis through week 92 in patients who responded to intravenous induction.

KEY POINTS

- Of patients achieving endoscopic improvement at week 44, 87.2% on guselkumab 100 mg every 8 weeks and 80.2% on 200 mg every 4 weeks maintained endoscopic improvement through week 92.
- Of patients achieving histologic improvement at week 44, 77.9% on guselkumab 100 mg every 8 weeks and 75.2% on 200 mg every 4 weeks maintained histologic improvement at week 92.
- Of patients achieving histologic remission (absence of neutrophils in mucosa, no crypt destruction, no erosions or ulcerations) at week 44, 71.2% in both guselkumab groups maintained remission at week 92.
- The dropout rate was low in the long-term extension, and as-observed analysis results were consistent with the nonresponder imputation analysis.
- Both guselkumab dose regimens showed similar long-term efficacy for endoscopic and histologic endpoints over two years of treatment.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/5cad9602-a813-11f0-a4f1-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.